ADAPT Study Basics

WHAT IS efgartigimod?

Efgartigimod is an investigational drug that is being developed by a company called argenx. Efgartigimod is thought to reduce autoimmune antibodies that contribute to neuromuscular weakness in gMG. During the ADAPT study, efgartigimod or a placebo is given by a healthcare professional through intravenous (IV) infusion over a period of one hour to evaluate the efficacy and safety of the investigational drug.

Who is Eligible
to participate in the adapt study?

If you are over 18 and have a diagnosis of generalized MG, you may be eligible to participate in this study.

Things you should know:

  • This study is open to gMG patients, regardless of autoantibody status. This includes patients who test positive for specific autoantibodies against AChR, MuSK, and LRP4 – and to patients who test negative.
  • You must be on a stable dose of your current gMG medicationsa.
  • Your doctor will need to see if you meet these and other eligibility criteria before you can be enrolled. These criteria will be evaluated by your doctor at screening.

WHAT ARE SOME GOALS OF THE STUDY?

The ADAPT study is designed to evaluate the impact of efgartigimod on:

MG – Activities of Daily Living

(MG-ADL)

Safety